Detailed Assessment of 18F-THK5351 Distribution Pattern in the Midbrain: Comparison With Progressive Supranuclear Palsy and Corticobasal Syndrome.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
medline:
11
9
2023
pubmed:
8
9
2023
entrez:
8
9
2023
Statut:
ppublish
Résumé
18F-THK5351 PET is used to image ongoing astrogliosis by estimating monoamine oxidase B levels. 18F-THK5351 preferentially accumulates around the substantia nigra (SN) and periaqueductal gray (PG) in the midbrain under healthy conditions and exhibits a "trimodal pattern." In progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), the midbrain 18F-THK5351 uptake can be increased by astrogliosis, collapsing the "trimodal pattern." We aimed to elucidate cases in which the "trimodal pattern" collapses in PSP and CBS. Participants in the PSP (n = 11), CBS (n = 17), Alzheimer disease (n = 11), and healthy control (n = 8) groups underwent 18F-THK5351 PET. Volumes of interest (VOIs) were placed on the SN, PG, and their midpoints. The midbrain uptake ratio (MUR) was calculated to assess the trimodal pattern as follows: MUR = (VOI value on the midpoint)/(VOI value on the SN and PG). Approximately, the trimodal pattern can be identified at MUR <1 but not at MUR >1. Compared with the healthy control group, MUR significantly increased in the PSP (P < 0.01) and CBS (P < 0.01) groups, but was unchanged in the Alzheimer disease group (P = 0.10). In the PSP group, all patients, including 2 with mild symptoms and a short disease duration, showed MUR >1. In the CBS group, MUR varied widely. In PSP, the trimodal pattern can collapse even in the early phase when symptoms are mild. In CBS, the trimodal pattern may or may not collapse depending on the underlying pathology.
Sections du résumé
BACKGROUND
BACKGROUND
18F-THK5351 PET is used to image ongoing astrogliosis by estimating monoamine oxidase B levels. 18F-THK5351 preferentially accumulates around the substantia nigra (SN) and periaqueductal gray (PG) in the midbrain under healthy conditions and exhibits a "trimodal pattern." In progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), the midbrain 18F-THK5351 uptake can be increased by astrogliosis, collapsing the "trimodal pattern." We aimed to elucidate cases in which the "trimodal pattern" collapses in PSP and CBS.
PATIENTS AND METHODS
METHODS
Participants in the PSP (n = 11), CBS (n = 17), Alzheimer disease (n = 11), and healthy control (n = 8) groups underwent 18F-THK5351 PET. Volumes of interest (VOIs) were placed on the SN, PG, and their midpoints. The midbrain uptake ratio (MUR) was calculated to assess the trimodal pattern as follows: MUR = (VOI value on the midpoint)/(VOI value on the SN and PG). Approximately, the trimodal pattern can be identified at MUR <1 but not at MUR >1.
RESULTS
RESULTS
Compared with the healthy control group, MUR significantly increased in the PSP (P < 0.01) and CBS (P < 0.01) groups, but was unchanged in the Alzheimer disease group (P = 0.10). In the PSP group, all patients, including 2 with mild symptoms and a short disease duration, showed MUR >1. In the CBS group, MUR varied widely.
CONCLUSIONS
CONCLUSIONS
In PSP, the trimodal pattern can collapse even in the early phase when symptoms are mild. In CBS, the trimodal pattern may or may not collapse depending on the underlying pathology.
Identifiants
pubmed: 37682599
doi: 10.1097/RLU.0000000000004815
pii: 00003072-202310000-00001
doi:
Substances chimiques
THK5351
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-846Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Harada R, Ishiki A, Kai H, et al. Correlations of (18)F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med . 2018;59:671–674.
Ng KP, Therriault J, Kang MS, et al. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [ 18 F]THK5351 uptake in progressive supranuclear palsy. Neuroimage Clin . 2019;24:102091.
Ishiki A, Harada R, Kai H, et al. Neuroimaging-pathological correlations of [ 18 F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun . 2018;6:53.
Ishibashi K, Miura Y, Tago T, et al. Distribution pattern of the monoamine oxidase B ligand, 18 F-THK5351, in the healthy brain. Clin Nucl Med . 2022;47:e489–e495.
Ishibashi K, Kameyama M, Tago T, et al. Potential use of 18 F-THK5351 PET to identify Wallerian degeneration of the pyramidal tract caused by cerebral infarction. Clin Nucl Med . 2017;42:e523–e524.
Ishibashi K, Miura Y, Hirata K, et al. 18 F-THK5351 PET can identify astrogliosis in multiple sclerosis plaques. Clin Nucl Med . 2020;45:e98–e100.
Ishibashi K, Miura Y, Hirata K, et al. Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using (18)F-THK5351 positron emission tomography. BMC Med Imaging . 2020;20:81.
Ishibashi K, Kameyama M, Miura Y, et al. Head-to-head comparison of the two MAO-B radioligands, 18 F-THK5351 and 11 C-L-Deprenyl, to visualize astrogliosis in patients with neurological disorders. Clin Nucl Med . 2021;46:e31–e33.
Tago T, Toyohara J, Sengoku R, et al. Monoamine oxidase B binding of 18 F-THK5351 to visualize glioblastoma and associated gliosis: an autopsy-confirmed case. Clin Nucl Med . 2019;44:507–509.
Higashihara M, Ishibashi K, Tokumaru AM, et al. Brain PET imaging of 11 C-methionine, 18 F-FDG, and 18 F-THK5351 in a case of lymphomatoid granulomatosis. Clin Nucl Med . 2022;47:e749–e751.
Higashihara M, Ishibashi K, Tokumaru AM, et al. 18 F-THK5351 PET can identify core lesions in different amyotrophic lateral sclerosis phenotypes. Clin Nucl Med . 2021;46:e582–e583.
Ezura M, Kikuchi A, Okamura N, et al. (18)F-THK5351 positron emission tomography imaging in neurodegenerative tauopathies. Front Aging Neurosci . 2021;13:761010.
Aiba I, Hashizume Y, Yoshida M, et al. Relationship between brainstem MRI and pathological findings in progressive supranuclear palsy—study in autopsy cases. J Neurol Sci . 1997;152:210–217.
Schonecker S, Brendel M, Palleis C, et al. PET imaging of astrogliosis and tau facilitates diagnosis of parkinsonian syndromes. Front Aging Neurosci . 2019;11:249.
Nam G, Jeong HJ, Kang JM, et al. (18)F-THK5351 PET imaging in the behavioral variant of frontotemporal dementia. Dement Neurocogn Disord . 2018;17:163–173.
Jeong HJ, Yoon CW, Seo S, et al. Relationships between [(1)(8)F]-THK5351 retention and language functions in primary progressive aphasia. J Clin Neurol . 2019;15:527–536.
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol . 2020;140:99–119.
Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology . 2014;34:555–570.
Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord . 2017;32:853–864.
Harada R, Okamura N, Furumoto S, et al. 18 F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med . 2016;57:208–214.
Lockhart SN, Baker SL, Okamura N, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351. PloS One . 2016;11:e0158460.
Otake S, Taoka T, Maeda M, et al. A guide to identification and selection of axial planes in magnetic resonance imaging of the brain. Neuroradiol J . 2018;31:336–344.
Koga S, Josephs KA, Aiba I, et al. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry . 2022;93:919–929.
Chung EJ, Cho HJ, Jang W, et al. A case of pathologically confirmed corticobasal degeneration initially presenting as progressive supranuclear palsy syndrome. J Korean Med Sci . 2022;37:e183.
Shimizu S, Imabayashi E, Takenoshita N, et al. Case of progressive supranuclear palsy detected by tau imaging with [ 18 F]THK-5351 before the appearance of characteristic clinical features. Geriatr Gerontol Int . 2018;18:501–502.
Wagatsuma K, Sakata M, Ishibashi K, et al. Direct comparison of brain [(18)F]FDG images acquired by SiPM-based and PMT-based PET/CT: phantom and clinical studies. EJNMMI Phys . 2020;7:70.